These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29246316)

  • 1. As Technologies for Nucleotide Therapeutics Mature, Products Emerge.
    Beierlein JM; McNamee LM; Ledley FD
    Mol Ther Nucleic Acids; 2017 Dec; 9():379-386. PubMed ID: 29246316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity.
    Beierlein JM; McNamee LM; Walsh MJ; Ledley FD
    Clin Ther; 2015 Aug; 37(8):1643-51.e3. PubMed ID: 26243074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling timelines for translational science in cancer; the impact of technological maturation.
    McNamee LM; Ledley FD
    PLoS One; 2017; 12(3):e0174538. PubMed ID: 28346525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities.
    Beierlein JM; McNamee LM; Walsh MJ; Kaitin KI; DiMasi JA; Ledley FD
    Clin Ther; 2017 Jul; 39(7):1409-1425.e20. PubMed ID: 28652015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
    Taniguchi H; Suzuki Y; Imai K; Adachi Y
    Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The infinite possibilities of RNA therapeutics.
    Mollocana-Lara EC; Ni M; Agathos SN; Gonzales-Zubiate FA
    J Ind Microbiol Biotechnol; 2021 Dec; 48(9-10):. PubMed ID: 34463324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
    J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting RNA: A Transformative Therapeutic Strategy.
    Yin W; Rogge M
    Clin Transl Sci; 2019 Mar; 12(2):98-112. PubMed ID: 30706991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
    Hammond SM; Aartsma-Rus A; Alves S; Borgos SE; Buijsen RAM; Collin RWJ; Covello G; Denti MA; Desviat LR; Echevarría L; Foged C; Gaina G; Garanto A; Goyenvalle AT; Guzowska M; Holodnuka I; Jones DR; Krause S; Lehto T; Montolio M; Van Roon-Mom W; Arechavala-Gomeza V
    EMBO Mol Med; 2021 Apr; 13(4):e13243. PubMed ID: 33821570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
    Jing X; Arya V; Reynolds KS; Rogers H
    Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study toward practical use of oligonucleotide therapeutics].
    Inoue T; Yoshida T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):13-5. PubMed ID: 25707197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA therapeutics: updates and future potential.
    Zhang C; Zhang B
    Sci China Life Sci; 2023 Jan; 66(1):12-30. PubMed ID: 36100838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the delivery of RNA therapeutics: from concept to clinical reality.
    Kaczmarek JC; Kowalski PS; Anderson DG
    Genome Med; 2017 Jun; 9(1):60. PubMed ID: 28655327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
    Traber GM; Yu AM
    J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligonucleotide Therapeutics: From Discovery and Development to Patentability.
    Moumné L; Marie AC; Crouvezier N
    Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35213992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer.
    Takakura K; Kawamura A; Torisu Y; Koido S; Yahagi N; Saruta M
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.